Jiang J, Zhu Y, Jian G, Zhu W
Zhong Shan Hospital, Shanghai Medical University.
Chin Med J (Engl). 1995 Jun;108(6):459-61.
A randomized case-controlled trial of oral low-dose acyclovir (600-800 mg per day) has been conducted for the prevention of virus infections in 66 recipients of renal allografts since 1990. In comparison with the untreated controls, acyclovir could prevent herpes virus simplex (HSV), reduce morbidity of pneumonia from 10 cases (30%) to 3 cases (9%) (P < 0.05) and lower CMV-IgM positive rate from 30% to 12%. Serum Cr and BUN in acyclovir group were lower than those in control group. These results strongly suggested that oral administration low-dose acyclovir could prevent virus infections after renal transplantation.
自1990年以来，一项关于口服低剂量阿昔洛韦（每天600 - 800毫克）预防66例肾移植受者病毒感染的随机病例对照试验已经开展。与未治疗的对照组相比，阿昔洛韦可预防单纯疱疹病毒（HSV），将肺炎发病率从10例（30%）降至3例（9%）（P < 0.05），并将巨细胞病毒IgM阳性率从30%降至12%。阿昔洛韦组的血清肌酐和尿素氮低于对照组。这些结果有力地表明，口服低剂量阿昔洛韦可预防肾移植后的病毒感染。
